Drug Interaction Potential of Pro-Inflammatory Conditions

计划入组 150 人 · 首次发布于 2026 年 1 月 22 日

Monitoring of Inflammatory Conditions

计划入组 664 人 · 首次发布于 2022 年 7 月 14 日

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

计划入组 25 人 · 首次发布于 2025 年 3 月 7 日

Liprotamase protease

Niflumic acid

C₁₃H₉F₃N₂O₂

extracellular vesicle therapy (orthopedic conditions)

Nurix Therapeutics

United States

Ventyx Biosciences

United States

Antibe Therapeutics Inc

Canada

FDA Approves Celltrion's Avtozma, a Tocilizumab Biosimilar, for Multiple Inflammatory Conditions

MoonLake Immunotherapeutics Advances Sonelokimab Through Phase 3 Trials for Multiple Inflammatory Conditions

China Medical System's MG-K10 Advances in Phase III Trials for Multiple Inflammatory Conditions